BSI-730, a bispecific antibody targeting HER2 and PD-L1 for the development of a first-in-class bispecific ADC

被引：0
|
作者：
Hao, Xiaoyao
Li, Hongyan
Liu, Xiaodong F.
Liu, Jinyu
Dai, Wenwen
Pan, Ying
Hu, Hui-Han
Li, Jun
Xia, Shukai
Lyu, Qun
Davis, Hugh M.
Chen, Mingjiu
Peng, Zeyu
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-3135
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3135
引用
收藏
页数：2
相关论文
共 50 条
  • [21] PD-L1/TIGIT bispecific antibody showed survival advantage in animal model
    Mu, Songlin
    Liang, Zhijuan
    Wang, Yongmei
    Chu, Wendi
    Chen, Yi-Li
    Wang, Qi
    Wang, Guifeng
    Wang, Chunhe
    CLINICAL AND TRANSLATIONAL MEDICINE, 2022, 12 (05):
  • [22] A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3
    Rau, Alexander
    Kocher, Katharina
    Rommel, Mirjam
    Kuehl, Lennart
    Albrecht, Maximilian
    Gotthard, Hannes
    Aschmoneit, Nadine
    Noll, Bettina
    Olayioye, Monilola A.
    Kontermann, Roland E.
    Seifert, Oliver
    MABS, 2021, 13 (01)
  • [23] Construction and Preclinical Evaluation of a 124I-Labeled Bispecific Antibody NB12 Targeting PD-L1 and PD-L2
    Yao, Yuan
    Zhu, Hua
    Yang, Zhi
    Li, Nan
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [24] Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition
    Gu, Chang-ling
    Zhu, Hai-xia
    Deng, Lan
    Meng, Xiao-qing
    Li, Kai
    Xu, Wei
    Zhao, Le
    Liu, Yue-qin
    Zhu, Zhen-ping
    Huang, Hao-min
    ACTA PHARMACOLOGICA SINICA, 2022, 43 (03) : 672 - 680
  • [25] Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition
    Chang-ling Gu
    Hai-xia Zhu
    Lan Deng
    Xiao-qing Meng
    Kai Li
    Wei Xu
    Le Zhao
    Yue-qin Liu
    Zhen-ping Zhu
    Hao-min Huang
    Acta Pharmacologica Sinica, 2022, 43 : 672 - 680
  • [26] Preclinical toxicology and pharmacology for the 4-1BB/HER2 bispecific PRS-343: A first-in-class costimulatory T cell engager
    Hinner, Marlon J.
    Aiba, Rachida-Siham Bel
    Jaquin, Thomas
    Berger, Sven
    Durr, Manuela
    Schlosser, Corinna
    Allersdorfer, Andrea
    Rothe, Christine
    Matis, Louis A.
    Olwill, Shane A.
    CANCER RESEARCH, 2017, 77
  • [27] A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance
    Yap, Timothy A.
    LoRusso, Patricia M.
    Wong, Deborah J.
    Hu-Lieskovan, Siwen
    Papadopoulos, Kyriakos P.
    Holz, Josefin-Beate
    Grabowska, Urszula
    Gradinaru, Cristian
    Leung, Kin-Mei
    Marshall, Sylwia
    Reader, Claire S.
    Russell, Roslin
    Sainson, Richard C. A.
    Seal, Claire J.
    Shepherd, Christopher J.
    Germaschewski, Fiona
    Gliddon, Daniel
    Stern, Omer
    Young, Lesley
    Brewis, Neil
    Kayitalire, Louis
    Morrow, Michelle
    CLINICAL CANCER RESEARCH, 2023, 29 (05) : 888 - 898
  • [28] Development of Plant-Derived Bispecific Monoclonal Antibody Targeting PD-L1 and CTLA-4 against Mouse Colorectal Cancer
    Bulaon, Christine Joy I.
    Khorattanakulchai, Narach
    Rattanapisit, Kaewta
    Sun, Hongyan
    Pisuttinusart, Nuttapat
    Phoolcharoen, Waranyoo
    PLANTA MEDICA, 2024, 90 (04) : 305 - 315
  • [29] Enhancing ovarian cancer treatment by synergistically targeting HER2 and PD-L1
    Zhang, Shuo
    Pan, Qi
    Wang, Kangchun
    MOLECULAR THERAPY ONCOLOGY, 2025, 33 (01):
  • [30] Comparative Characterization of Different Molecular Formats of Bispecific Antibodies Targeting EGFR and PD-L1
    Mohan, Nishant
    Agrawal, Atul
    Shen, Yi
    Winarski, Katie L.
    Endo, Yukinori
    Dokmanovic, Milos
    Schmiel, Deborah
    Zheng, Jiwen
    Rotstein, David S.
    Pelosof, Lorraine C.
    Wu, Wen Jin
    PHARMACEUTICS, 2022, 14 (07)
12345